Nibrozetone - EpicentRx
Alternative Names: RRx-001Latest Information Update: 12 Aug 2024
At a glance
- Originator RadioRx
- Developer EpicentRx; SciClone Pharmaceuticals; The University of Queensland
- Class Anti-inflammatories; Antianaemics; Antidementias; Antifibrotics; Antineoplastics; Antiparkinsonians; Azetidines; Cytoprotectives; Nitro compounds; Radiosensitisers; Small molecules
- Mechanism of Action CD47 antigen inhibitors; Free radical stimulants; Inflammasome inhibitors; Macrophage stimulants; NLRP3 protein inhibitors; Proto-oncogene protein c-myc inhibitors; SIRPA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Small cell lung cancer
- Phase II Cholangiocarcinoma; Colorectal cancer; Mucositis; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer
- Phase I CNS cancer; Solid tumours
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Endometriosis; Myocardial infarction; Parkinson's disease; Pulmonary fibrosis
- No development reported Brain metastases; Glioblastoma; Glioma; Lymphoma; Multiple myeloma; Sickle cell anaemia
Most Recent Events
- 29 Jul 2024 EpicentRx terminates the phase I trial in Solid tumours (Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA due to low enrollment (IV) (NCT04525014)
- 02 Apr 2024 EpicentRx initiates a phase II KEVLARx trial in Mucositis in USA (IV,Injection) (NCT05966194)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Brain metastases(Combination therapy) in USA (IV)